Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Inc.(MYL - Analyst Report)) recently announced that it has launched its generic version of Pfizer's (PFE - Analyst Report) Dilantin Chewable Tablets (phenytoin - 50 mg). The company started shipping the product following the receipt of final US Food and Drug Administration (FDA) approval.

Dilantin is approved for controlling generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. It is also indicated for the prevention and treatment of seizures at the time of or after neurosurgery. According to IMS Health, phenytoin generated US revenues of approximately $16.5 million for the 12 months ending September 30, 2012.

Mylan had 185 ANDAs pending FDA clearance, targeting $80.6 billion in sales annually. Mylan believes that about 35 of these pending abbreviated new drug applications (ANDAs) are first-to-file opportunities, representing $21.2 billion in branded sales. The revenue figures are as per IMS Health for the 12 months ending June 30, 2012.

Our Recommendation

Mylan’s geographic reach and product depth along with a robust generic product pipeline are contributing to the company’s overall growth. However, we remain cautious of the company’s performance in the Europe, Middle East and Africa (EMEA) region.

Additionally, as most of the large branded drugs are due to lose patent exclusivity within the 2017-2018 period, we have little visibility on the growth prospects of generic companies like Mylan beyond that timeframe.

In view of these challenges, we see limited upside from current levels and maintain a Neutral recommendation on Mylan. The stock carries a Zacks #3 Rank (Hold) in the short run.

Currently, pharma companies like Valeant Pharmaceuticals Internat (VRX - Snapshot Report), carry a Zacks #1 Rank (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.63 +6.47%
BOFL HOLDING BOFI 85.73 +5.50%
CELL THERAPE CTIC 3.14 +5.04%
RAMBUS INC RMBS 12.28 +4.13%
SHORETEL INC SHOR 8.03 +3.08%